Xiaochao Ma1, Jeffrey R Idle, Frank J Gonzalez. 1. National Cancer Institute, Laboratory of Metabolism, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract
BACKGROUND: The pregnane X receptor (PXR; NR1I2), a member of the nuclear receptor superfamily, regulates the expression of metabolic enzymes and transporters involved in the response of mammals to their chemical environment. OBJECTIVE: To summarize the functions and clinical implications of PXR. METHODS: In the current review, the clinical implications of PXR are discussed, and the use of genetically engineered PXR mouse models is highlighted. RESULTS/ CONCLUSION: Recent advances in mouse models, including Pxr-null and PXR-humanized mice, provide in vivo tools for evaluating the physiological functions of PXR and its role in controlling xenobiotic metabolism and transport. By using the PXR knockout and humanized mouse models, PXR was found to influence drug-drug interactions, hepatic steatosis, and the homeostasis of vitamin D, bile acids, and steroid hormones. PXR was also shown to influence inflammatory bowel diseases.
BACKGROUND: The pregnane X receptor (PXR; NR1I2), a member of the nuclear receptor superfamily, regulates the expression of metabolic enzymes and transporters involved in the response of mammals to their chemical environment. OBJECTIVE: To summarize the functions and clinical implications of PXR. METHODS: In the current review, the clinical implications of PXR are discussed, and the use of genetically engineered PXRmouse models is highlighted. RESULTS/ CONCLUSION: Recent advances in mouse models, including Pxr-null and PXR-humanized mice, provide in vivo tools for evaluating the physiological functions of PXR and its role in controlling xenobiotic metabolism and transport. By using the PXR knockout and humanized mouse models, PXR was found to influence drug-drug interactions, hepatic steatosis, and the homeostasis of vitamin D, bile acids, and steroid hormones. PXR was also shown to influence inflammatory bowel diseases.
Authors: Linda B Moore; Jodi M Maglich; David D McKee; Bruce Wisely; Timothy M Willson; Steven A Kliewer; Millard H Lambert; John T Moore Journal: Mol Endocrinol Date: 2002-05
Authors: P I Mackenzie; P A Gregory; D A Gardner-Stephen; R H Lewinsky; B R Jorgensen; T Nishiyama; Wen Xie; A Radominska-Pandya Journal: Curr Drug Metab Date: 2003-06 Impact factor: 3.731
Authors: Gang Luo; Mark Cunningham; Sean Kim; Tim Burn; Jianrong Lin; Michael Sinz; Geraldine Hamilton; Christopher Rizzo; Summer Jolley; Darryl Gilbert; April Downey; Daniel Mudra; Richard Graham; Kathy Carroll; Jindong Xie; Ajay Madan; Andrew Parkinson; Dave Christ; Bernard Selling; Edward LeCluyse; Liang-Shang Gan Journal: Drug Metab Dispos Date: 2002-07 Impact factor: 3.922
Authors: Bryan Goodwin; Karine C Gauthier; Michihisa Umetani; Michael A Watson; Matthew I Lochansky; Jon L Collins; Eran Leitersdorf; David J Mangelsdorf; Steven A Kliewer; Joyce J Repa Journal: Proc Natl Acad Sci U S A Date: 2002-12-30 Impact factor: 11.205